GeoVax Labs (NASDAQ:GOVX – Get Free Report) and Yarrow Bioscience (NASDAQ:YARW – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.
Institutional and Insider Ownership
6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares GeoVax Labs and Yarrow Bioscience”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeoVax Labs | $2.49 million | 0.62 | -$21.47 million | ($11.34) | -0.02 |
| Yarrow Bioscience | $570,000.00 | 92.30 | -$26.48 million | ($14.64) | -1.35 |
GeoVax Labs has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for GeoVax Labs and Yarrow Bioscience, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
GeoVax Labs currently has a consensus price target of $150.00, suggesting a potential upside of 72,015.38%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 194.36%. Given GeoVax Labs’ higher possible upside, equities analysts clearly believe GeoVax Labs is more favorable than Yarrow Bioscience.
Profitability
This table compares GeoVax Labs and Yarrow Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeoVax Labs | N/A | -743.64% | -394.74% |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
Volatility and Risk
GeoVax Labs has a beta of 3.69, indicating that its share price is 269% more volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.
